Cencora Q3 fiscal 2026 slides show specialty strength, raised guidance

Cencora released its Q3 fiscal 2026 earnings slides showing revenue of $321.3B, up 9.3% year-over-year, alongside gross margin of 3.6% and net margin of 0.5%, with diluted EPS of $7.96. The company also raised its full-year guidance, and management specifically called out strength in its specialty pharmaceutical segment as a driver of the quarter.

Cencora operates as one of the largest pharmaceutical distributors in the U.S., a business defined by thin margins on enormous volume. A guidance raise in this model typically signals either better-than-expected specialty drug volumes, favorable generic/brand mix, or disciplined cost control flowing through to the bottom line — all of which show up disproportionately given how thin the 3.6% gross and 0.5% net margins already are. The raise touches sentiment across the broader pharma distribution peer set that trades on similar volume-and-mix dynamics.

The setup from here is straightforward: a raised guide after a 9.3% revenue growth quarter is constructive, but the stock's reaction will hinge on whether the raise reflects durable specialty-segment tailwinds (GLP-1s, oncology, biosimilars flowing through specialty channels) versus one-time timing benefits. Because no explicit new guidance figures were provided in the summary beyond the raise itself, and no analyst consensus or price-target data was supplied, the market reaction and follow-through are the key things to watch, along with any post-earnings commentary on specialty growth durability into fiscal 2027.